Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Echo Therapeutics Facing Major Execution Risks In A Very Competitive Market

(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)

I go back a long way with the diabetes space, and glucose monitoring in particular, as that was a big part of my coverage group back in the sell-side research days. During that time, there was the occasional MiniMed (acquired by Medtronic (NYSE:MDT)) or TheraSense (acquired by Abbott Labs (NYSE:ABT)), but quite a few Integs for every one of those successes. Today, Echo Therapeutics (NASDAQ:ECTE) is grinding along, hoping that its Symphony tCGM System vaults it into the winner's circle with...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details